BusinessSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressBy Nasdaq OMXJun 14, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceBy Nasdaq OMXMar 15, 2017, 11:00 AM UTC
BusinessSummit Therapeutics to Participate in February Investor ConferencesBy Nasdaq OMXFeb 2, 2017, 12:00 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessPositive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile InfectionBy Nasdaq OMXApr 11, 2016, 11:00 AM UTC
